CA3253889A1 - RIFABUTINE ANALOGUES FOR THE TREATMENT OF A DISEASE - Google Patents

RIFABUTINE ANALOGUES FOR THE TREATMENT OF A DISEASE

Info

Publication number
CA3253889A1
CA3253889A1 CA3253889A CA3253889A CA3253889A1 CA 3253889 A1 CA3253889 A1 CA 3253889A1 CA 3253889 A CA3253889 A CA 3253889A CA 3253889 A CA3253889 A CA 3253889A CA 3253889 A1 CA3253889 A1 CA 3253889A1
Authority
CA
Canada
Prior art keywords
alkyl
optionally substituted
halogen
independently
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3253889A
Other languages
English (en)
French (fr)
Inventor
Kevin ANTRAYGUES
Marilyne BOUROTTE
Glenn E. Dale
Olivier Defert
Marc Gitzinger
Sergio Lociuro
Mathieu MAINGOT
Vincent Trebosc
Nicolas Willand
Original Assignee
Bioversys AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bioversys AG filed Critical Bioversys AG
Publication of CA3253889A1 publication Critical patent/CA3253889A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA3253889A 2022-04-11 2023-04-06 RIFABUTINE ANALOGUES FOR THE TREATMENT OF A DISEASE Pending CA3253889A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22167670.3 2022-04-11
EP22167670 2022-04-11
PCT/EP2023/059154 WO2023198597A1 (en) 2022-04-11 2023-04-06 Rifabutin analogs for the treatment of disease

Publications (1)

Publication Number Publication Date
CA3253889A1 true CA3253889A1 (en) 2023-10-19

Family

ID=81306910

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3253889A Pending CA3253889A1 (en) 2022-04-11 2023-04-06 RIFABUTINE ANALOGUES FOR THE TREATMENT OF A DISEASE

Country Status (7)

Country Link
US (1) US20250235434A1 (cg-RX-API-DMAC10.html)
EP (1) EP4508053A1 (cg-RX-API-DMAC10.html)
JP (1) JP2025513019A (cg-RX-API-DMAC10.html)
CN (1) CN118974060A (cg-RX-API-DMAC10.html)
AU (1) AU2023251806A1 (cg-RX-API-DMAC10.html)
CA (1) CA3253889A1 (cg-RX-API-DMAC10.html)
WO (1) WO2023198597A1 (cg-RX-API-DMAC10.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025132358A1 (en) * 2023-12-21 2025-06-26 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of infectious diseases
EP4696694A1 (en) 2024-08-14 2026-02-18 BioVersys AG Antibiotic rifabutin analogs
EP4696695A1 (en) * 2024-08-14 2026-02-18 BioVersys AG Antibiotic rifabutin analogs
WO2026062070A1 (en) * 2024-09-18 2026-03-26 Galapagos Nv Compounds and pharmaceutical compositions thereof for the treatment of infectious diseases

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5262564A (en) 1992-10-30 1993-11-16 Octamer, Inc. Sulfinic acid adducts of organo nitroso compounds useful as retroviral inactivating agents anti-retroviral agents and anti-tumor agents
PT102807A (pt) 2002-07-09 2004-01-30 Inst Nac De Engenharia E Tecno Derivados n-substituidos de rifabutina uteis como agentes antimicrobianos, processo para a sua preparacao e sua utilizacao como medicamentos

Also Published As

Publication number Publication date
US20250235434A1 (en) 2025-07-24
EP4508053A1 (en) 2025-02-19
AU2023251806A1 (en) 2024-09-12
JP2025513019A (ja) 2025-04-22
WO2023198597A1 (en) 2023-10-19
CN118974060A (zh) 2024-11-15

Similar Documents

Publication Publication Date Title
WO2023198597A1 (en) Rifabutin analogs for the treatment of disease
EP3571189B1 (en) Pyridine compounds as allosteric shp2 inhibitors
EP3571199B1 (en) Bicyclic compounds as allosteric shp2 inhibitors
WO2024165591A1 (en) Rifabutin analogs for the treatment of bacterial diseases
EP4594330A1 (en) Rifabutin analogs for the treatment of disease
EP4452412B1 (en) Rifabutin analogs for the treatment of disease
WO2026037898A1 (en) Antibiotic rifabutin analogs
EP4469463B1 (en) Rifamycin derivatives for the treatment of diseases
EP4696694A1 (en) Antibiotic rifabutin analogs
SK277949B6 (en) Cis-2,8-dimethyl-2,3,4,4a,5,9b-hexahydro-5-(3-pyridinecarbonyle)- -1h-pyrido/4,3-b/indole and method of its preparation

Legal Events

Date Code Title Description
A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A00-A101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION RECEIVED - PCT

Effective date: 20240904

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 2ND ANNIV.) - STANDARD

Year of fee payment: 2

A00 Application filed

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A00-A102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: COMPLIANCE REQUIREMENTS DETERMINED MET

Effective date: 20250206

A15 Pct application entered into the national or regional phase

Free format text: ST27 STATUS EVENT CODE: A-1-1-A10-A15-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: NATIONAL ENTRY REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250206

P18 Priority claim added or amended

Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P18-P105 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: PRIORITY CLAIM REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250206

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20250218

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260318

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260318